2657613-87-9
Chemical Structure
Glecirasib
Synonym(s): JAB-21822; KRAS G12C inhibitor 36
- CAS No.: 2657613-87-9
- Formula:C31H26ClF4N7O2
- Molecular Weight:640.03
IUPAC Name: 4-(4-acryloylpiperazin-1-yl)-7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carbonitrile
InChIKey: QRRJEUIQLZNPIO-UHFFFAOYSA-N
SMILES: N#CC1=C(N2CCN(CC2)C(C=C)=O)C3=C(N=C(C4=C(N)C(F)=C(F)C(F)=C4F)C(Cl)=C3)N(C5=C(C)C=CN=C5C(C)C)C1=O
Biological Activity: Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glecirasib | 99.20% | Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1.
- [2]. Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J]. 2024.
- [3]. Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. J Med Chem. 2024 Aug 22;67(16):13534-13549. [Content Brief]
- [4]. Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J]. 2024.
Keywords
